Multiple myeloma is characterized by the accumulation of malignant plasma c
ells in the bone marrow and rarely cured by chemotherapy. Villunger et al.
showed that the neoplastic plasma cells express Fas ligand (FasL), which tr
ansmits ii signal of apoptosis upon ligation to Fas. and suggested that the
FasL suppresses the T-cells activated against malignant cells, resulting i
n escape from tumour immunity. We examined serum soluble Fast (sFasL) level
s in 35 multiple myeloma patients to evaluate the correlation between sFasL
levels and clinical characteristics. The serum sFasL levels were not affec
ted hy the disease status, serum monoclonal protein levels, or other progno
stic factors. We could not determine whether the expression of FasL is invo
lved in the poor clinical course of the disease.